Macomics
macomics.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$5.4M
1 round on record
Latest round
$5.4M
Venture round · Jul 2021 · 5 yr ago
Team
11-50
employees, estimated range
Backers
1
Epidarex Capital
The money's age
Long since its last round
62 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 10, 2024
New executive Macomics Announces Appointment of Simon Dew as New Chief Business Officer · macomics.com
Apr 11, 2024
Launched Macomics Unveils its Lead First-in-Class Anti-Pan-LILR Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024 · macomics.com
Oct 19, 2023
Board appointment Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director · macomics.com
Sep 29, 2023
Expanded Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB · macomics.com
Mar 23, 2023
Partnership Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer · YahooFinance
Jul 29, 2021
Raised a round Venture round $5.4M · led by Epidarex Capital · FinanzNachrichten.de
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2021 | $5.4M | Epidarex Capital lead | FinanzNachrichten.de |
Backed byfrom the funds' portfolios and accelerator catalogs
Epidarex Capital Similar startupsby what they do, their industry and backers
Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience…
At Pheast Therapeutics, we are developing new innate immune checkpoint inhibitors, including anti-CD24, to unleash the power of macrophages…
Delight.ai builds a living understanding of every customer—who they are, what they love, and what they need next.
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our…
Almetra is building the intelligence layer for manufacturing, giving teams a continuous understanding of what.
Vilya creates macrocycles using AI and synthetic biology, designing novel therapeutics inspired by nature, beyond evolution’s reach.
News
Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC platform in macrophage mediated antifibrotic therapy.
Read more
Report
Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease
Edinburgh and Cambridge, UK, 25 November 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC platform in macrophage mediated antifibrotic therapy. Macomics' ENIGMAC drug discovery platform is designed to
Read more
Report
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that i...
Read more
Report
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
Edinburgh and Cambridge, UK, 8 October 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC platform in neurodegeneration and neuroinflammation applications. Macomics' ENIGMAC drug discovery platform is d
Read more
Report
Macomics Team Scores Gold and Raises Over £600 in its Hyper-Triathlon Challenge in aid of Founder Prof. Jeffrey Pollard's Memorial Fund
Edinburgh and Cambridge, UK, 12 August 2024 - With Olympics drawn to a close, the team at Macomics Ltd, a leader in macrophage drug discovery, is celebrating its own achievement in raising over £600 in its Hyper-Triathlon Challenge. Started in 2023 in hon
Read more
Report
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems The collaboration will combine advance
Read more
Report
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapies Simon Dew brings over 25 years of experience in pharmaceutical business development to advance partnerships for Macomics' macrop
Read more
Report
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophages The collaboration will combine advanced human ex vivo models with new
Read more
Report
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe collaboration will combine advanced human ex vivo models with new t
Read more
Report
Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with pre-clinical data
Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with pre-clinical data
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Edinburgh
United Kingdom
Registered seat
10-50 est. staff
Financials
Total raised
$5.4M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $5.4M | Details |